Dr. Powell Discusses CPI-613 in Hematologic Malignancies

Bayard L. Powell, MD
Published: Tuesday, Jun 11, 2013

Bayard L. Powell, MD, the Director-At-Large and a Professor in Hematology & Oncology at the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses a phase I study that explored the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.

The well-tolerated toxicities and activity of CPI-613 has prompted further research of the agent as a treatment for patients with myelodysplastic syndromes, Powell notes. Additionally, a second phase I trial will be initiated to explore CPI-613 plus high-dose cytarabine as a treatment for patients with acute myeloid leukemia.

High levels of activity were observed with CPI-613, which is unusual for patients with advanced relapsed or refractory hematologic malignancies, Powell points out. As a result, further investigation into this agent is intriguing.

Bayard L. Powell, MD, the Director-At-Large and a Professor in Hematology & Oncology at the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses a phase I study that explored the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.

The well-tolerated toxicities and activity of CPI-613 has prompted further research of the agent as a treatment for patients with myelodysplastic syndromes, Powell notes. Additionally, a second phase I trial will be initiated to explore CPI-613 plus high-dose cytarabine as a treatment for patients with acute myeloid leukemia.

High levels of activity were observed with CPI-613, which is unusual for patients with advanced relapsed or refractory hematologic malignancies, Powell points out. As a result, further investigation into this agent is intriguing.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x